As reducing the amyloid fibril precursor protein concentration is known to slow amyloid formation and improve prognosis among patients with a variety of systemic amyloidoses, and as PPARα agonists (fibrates) significantly reduce hepatic APOC3 transcription35, 36, we postulate that fibrate therapy may have therapeutic potential for treatment of this new form of amyloidosis. This evidence concerns the gene PPARA and amyloidosis.